Just a summary of all the news articles that we could source from different places. A good way to make an investment decision is also to look at how actively the company is engaging with news sources to keep them in the news. In this day and age its critical to have a media presence.
Please consider a small donation if you think this website provides you with relevant information
| Date | Title | Source |
|---|---|---|
| 2024-03-12 4:31:10 am | Immunovant Awarded U.S. Patent for IMVT-1402 | GlobeNewsWire |
| 2024-03-08 6:35:3 am | Here's Why Immunovant, Inc. (IMVT) is Poised for a Turnaround After Losing -8.02% in 4 Weeks | Zacks |
| 2024-02-26 12:4:0 pm | 3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024 | InvestorPlace |
| 2024-02-23 8:22:24 pm | Immunovant Inc CFO Eva Barnett Sells 2,930 Shares | GuruFocus.com |
| 2024-02-14 2:4:33 am | We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth | Simply Wall St. |
| 2024-02-14 1:35:2 am | Immunovant Inc (IMVT) Reports Fiscal Q3 Results: Expands Clinical Programs Amid Rising R&D Costs | GuruFocus.com |
| 2024-02-13 9:29:46 pm | Q3 2024 Roivant Sciences Ltd Earnings Call | Thomson Reuters StreetEvents |
| 2024-02-13 4:26:0 am | Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus | Zacks |
| 2024-02-12 4:0:0 am | Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023 | GlobeNewswire |
Please consider a small donation if you think this website provides you with relevant information